Coronavirus disease 2019 (COVID-19) is a pandemic affecting more than 3 million people worldwide and carrying a case fatality rate exceeding 7% as of early May 2020.
1 New York, New York, has emerged as the most recent epicenter of the disease, with more than 150 000 confirmed cases and nearly 11 000 fatalities (as of April 26, 2020).
1 Preexisting cardiovascular diseases, such as hypertension, coronary artery disease, and diabetes, have been associated with an increased risk for COVID-19.
2-4 Disease severity appears to be driven not only by viral invasion and proliferation but also by an intense immune response marked by cytokine storm, myocardial injury, and death.
5,6 Recipients of heart transplant (HT) may be at an increased risk for infection and adverse outcomes with COVID-19 infection because of a number of comorbidities that are common following heart transplant, including hypertension, diabetes, and cardiac allograft vasculopathy. Moreover, while all require maintenance immunosuppression that predisposes recipients to a greater infectious risk, immunosuppression has also been theorized to be protective from cytokine storm. Preliminary case reports
7,8 have not indicated a disproportionate outcome of COVID-19 on the posttransplant population, and a survey
9 from China did not find an increased risk of infection among recipients of HT. In this article, we present a large case series of recipients of HT with COVID-19 and describe their presentation, disease course, outcomes, and immunosuppression management. The aim of this case series is to describe the outcomes of recipients of HT who are chronically immunosuppressed and develop COVID-19 and raise important questions about the role of the immune system in the disease process.